Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

5 Cancer Types With the Poorest Long-Term Outlook


5 Cancer Types With the Poorest Long-Term Outlook

There's arguably no scarier diagnosis a patient can receive from their doctor than cancer. But the grim reality, based on data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program, is that 38.5% of all people, men and women, will be diagnosed with cancer at some point during their lifetime. 

This year alone, the American Cancer Society (ACS) is projecting 1.69 million Americans will be diagnosed with cancer, and that nearly 601,000 people will die as a direct result of cancer. That makes it the No. 2 killer in the U.S., trailing only heart disease. However, with heart disease drugs improving and eating habits getting potentially healthier, cancer is expected to surpass heart disease and become the nation's leading killer by the next decade. 

Image source: Getty Images.

Continue reading


Source: Fool.com

Bristol-Myers Squibb Stock

€41.74
1.860%
There is an upward development for Bristol-Myers Squibb compared to yesterday, with an increase of €0.77 (1.860%).
With 9 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 70 € shows a very positive potential of 67.7% compared to the current price of 41.74 € for Bristol-Myers Squibb.
Like: 0
BMY
Share

Comments